These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 31766279)

  • 61. [Management of multiple myeloma in the relapsed/refractory patient].
    Tabayashi T
    Rinsho Ketsueki; 2019; 60(9):1257-1264. PubMed ID: 31597851
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
    Moreau P
    Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Investigational treatments for multiple myeloma.
    Bringhen S; Avonto I; Magarotto V; Boccadoro M; Palumbo A
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1565-82. PubMed ID: 17107282
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
    Malard F; Harousseau JL; Mohty M
    Cancer Treat Rev; 2017 Jan; 52():41-47. PubMed ID: 27888768
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
    Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
    Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Novel agents in the treatment of multiple myeloma: a review about the future.
    Naymagon L; Abdul-Hay M
    J Hematol Oncol; 2016 Jun; 9(1):52. PubMed ID: 27363832
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR).
    Willenbacher W; Thangavadivel S; Greil R; Willenbacher E; Weger R; Manzl C; Jöhrer K; Brunner A
    Leuk Lymphoma; 2016 Oct; 57(10):2330-41. PubMed ID: 26880040
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Panobinostat: a review of trial results and future prospects in multiple myeloma.
    Libby EN; Becker PS; Burwick N; Green DJ; Holmberg L; Bensinger WI
    Expert Rev Hematol; 2015 Feb; 8(1):9-18. PubMed ID: 25410127
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
    Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
    Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.
    Walker ZJ; VanWyngarden MJ; Stevens BM; Abbott D; Hammes A; Langouët-Astrie C; Smith CA; Palmer BE; Forsberg PA; Mark TM; Jordan CT; Sherbenou DW
    Blood Adv; 2020 Apr; 4(8):1628-1639. PubMed ID: 32311014
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches.
    Szalat R; Munshi NC
    Am Soc Clin Oncol Educ Book; 2016; 35():e442-8. PubMed ID: 27249752
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The role of SLAMF7 in multiple myeloma: impact on therapy.
    Boudreault JS; Touzeau C; Moreau P
    Expert Rev Clin Immunol; 2017 Jan; 13(1):67-75. PubMed ID: 27376202
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.
    Ziccheddu B; Biancon G; Bagnoli F; De Philippis C; Maura F; Rustad EH; Dugo M; Devecchi A; De Cecco L; Sensi M; Terragna C; Martello M; Bagratuni T; Kastritis E; Dimopoulos MA; Cavo M; Carniti C; Montefusco V; Corradini P; Bolli N
    Blood Adv; 2020 Mar; 4(5):830-844. PubMed ID: 32126144
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Getting to the root of the problem: the causes of relapse in multiple myeloma.
    Chan Chung KC; Tiedemann RE
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):251-4. PubMed ID: 24397833
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs.
    Ocio EM; Mateos MV; San-Miguel JF
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1075-87. PubMed ID: 22621161
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
    Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y
    Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Drug resistance in multiple myeloma: approaches to circumvention.
    Dalton WS; Jove R
    Semin Oncol; 1999 Oct; 26(5 Suppl 13):23-7. PubMed ID: 10528891
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.
    Anwer F; Gee KM; Iftikhar A; Baig M; Russ AD; Saeed S; Zar MA; Razzaq F; Carew J; Nawrocki S; Al-Kateb H; Cavalcante Parr NN; McBride A; Valent J; Samaras C
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):397-405. PubMed ID: 31036508
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Proteasome inhibitors in treatment of multiple myeloma].
    Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
    Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.
    Bianchi G; Ghobrial IM
    Leuk Lymphoma; 2013 Feb; 54(2):229-41. PubMed ID: 22897729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.